Shots:

• MegaPharm to get exclusive commercialization rights for Lurbinectedin in Israel and PharmaMar to retain production rights for the product
• The focus of the agreement is to strengthen MegaPharm’s oncology portfolio in the Israeli market
• Lurbinectedin (PM1183) is selective inhibitor of the oncogenic transcription programs and its NDA application is currently being evaluated by the FDA under “Priority Review” status targeted to treat NSCLC with provided PDUFA date Aug 16- 2020

Click here to read full press release/ article | Ref: PharmaMar | Image: Twitter